Repositorio Dspace

Listar por autor "Xicoy, Blanca"

Listar por autor "Xicoy, Blanca"

Ordenar por:Orden:Resultados:

  • AML typical mutations ( CEBPA, FLT3, NPM1) identify a high-risk chronic myelomonocytic leukemia independent of CPSS molecular 
    Castaño-Diez, Sandra; López-Guerra, Mónica; Zugasti, Inés; Calvo, Xavier; Schulz, Felicitas-Isabel; Avendano, Alejandro; Mora, Elvira; Falantes, José; Azaceta, Gemma; Ibáñez, Maríam; Chen-Liang, Tzu-Hua; Notano, Cristina; Amer, Neus; Palomo, Laura; Pomares, Helena; Vila, Jordi; Bernal-del-Castillo, Teresa; Jiménez-Vicente, Carlos; Esteban, Daniel; Guijarro, Francesca; Álamo, José; Cortés-Bullich, Albert; Torrecillas-Mayayo, Victor; Triguero, Ana; Mont-de-Torres, Lucía; Carcelero, Ester; Cardus, Aina; Germing, Ulrich; Betz, Beate; Rozman, María; Arenillas, Leónor; Zamora, Lurdes; Diez-Campelo, María; Xicoy, Blanca; Esteve, Jordi; Díaz-Bey, Marina (ELSEVIER, 2025-01-14)
    Mutations commonly associated with acute myeloid leukemia (AML), such as CEBPA, FLT3, IDH1/2, and NPM1, are rarely found in chronic myelomonocytic leukemia (CMML), and their prognostic significance in CMML has not been ...
  • Association between Germline Single-Nucleotide Variants in ADME Genes and Major Molecular Response to Imatinib in Chronic Myeloid Leukemia Patients 
    Estrada, Natalia; Zamora, Lurdes; Ferrer-Marín, Francisca; Palomo, Laura; García, Olga; Vélez, Patricia; de-la-Fuente, Iris; Sagüés, Miguel; Cabezón, Marta; Cortés, Montserrat; Omar-Vallansot, Rolando; Alicia-Senin-Magan, María; Boque, Concepción; Xicoy, Blanca (MDPI, 2022-10)
    Imatinib is the most common first-line tyrosine kinase inhibitor (TKI) used to treat chronic-phase chronic myeloid leukemia (CP-CML). However, only a proportion of patients achieve major molecular response (MMR), so there ...
  • Clinical and Genomic-Based Decision Support System to Define the Optimal Timing of Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Myelodysplastic Syndromes 
    Tentori, Cristina-Astrid; Gregorio, Caterina; Robin, Marie; Gagelmann, Nico; Gurnari, Carmelo; Ball, Somedeb; Caballero-Berrocal, Juan-Carlos; Lanino, Luca; D'Amico, Saverio; Spreafico, Marta; Maggioni, Giulia; Travaglino, Erica; Sauta, Elisabetta; Meggendorfer, Manja; Zhao, Lin-Pierre; Campagna, Alessia; Savevski, Víctor; Santoro, Armando; Al-Ali, Najla; Sallman, David; Sole, Francesc; García-Manero, Guillermo; Germing, Ulrich; Kroger, Nicolaus; Kordasti, Shahram; Santini, Valeria; Sanz, Guillermo; Kern, Wolfgang; Platzbecker, Uwe; Díez-Campelo, María; Maciejewski, Jaroslaw-P; Ades, Lionel; Fenaux, Pierre; Haferlach, Torsten; Zeidan, Amer-M; Castellani, Gastone; Komrokji, Rami; Ieva, Francesca; Della-Porta, Matteo-Giovanni; Bernardi, Massimo; Di-Grazia, Carmen; Vago, Luca; Rivoli, Giulia; Borin, Lorenza; Chiusolo, Patrizia; Giaccone, Luisa; Voso, María-Teresa; Bewersdorf, Jan-Philipp; Nibourel, Olivier; Díaz-Beya, Marina; Jerez-Cayuela, Andrés; Hernández, Francisca; Velázquez-Kennedy, Kyra; Xicoy, Blanca; Ubezio, Marta; Russo, Antonio; Todisco, Gabriele; Mannina, Daniele; Bramanti, Stefania; Zampini, Matteo; Riva, Elena; Bicchieri, Marilena; Asti, Gianluca; Viviani, Filippo; Buizza, Alessandro; Tinterri, Benedetta; Kubasch, Anne-Sophie; Bacigalupo, Andrea; Raiola, Anna-María; Rambaldi, Alessandro; Passamonti, Francesco; Ciceri, Fabio (Lippincott Williams and Wilkins, 2024)
    PURPOSE: Allogeneic hematopoietic stem-cell transplantation (HSCT) is the only potentially curative treatment for patients with myelodysplastic syndromes (MDS). Several issues must be considered when evaluating the benefits ...
  • e14a2 Transcript Favors Treatment-Free Remission in Chronic Myeloid Leukemia When Associated with Longer Treatment with Tyrosine Kinase Inhibitors and Sustained Deep Molecular Response 
    Marce, Silvia; Méndez, Aleix; Xicoy, Blanca; Estrada, Natalia; Cabezón, Marta; Sturla, Antonella-Luciana; Ratia-García, Miriam; Angona, Anna; Amat, Paula; Escribano-Serrat, Silvia; Scalzulli, Emilia; Morgades, Mireia; Senin, Alicia; Hernández-Boluda, Juan-Carlos; Ferrer-Marín, Francisca; Anguita, Eduardo; Cortés, Montserrat; Plensa, Esther; Breccia, Massimo; García-Gutiérrez, Valentín; Zamora, Lurdes (MDPI, 2024-02)
    e13a2 and e14a2 are the most frequent transcript types of the BCR::ABL1 fusion gene in chronic myeloid leukemia (CML). The current goal with tyrosine kinase inhibitors (TKI) is to achieve sustained deep molecular response ...
  • Impact of BCR-ABL1 Transcript Type on Response, Treatment-Free Remission Rate and Survival in Chronic Myeloid Leukemia Patients Treated with Imatinib 
    Marce, Silvia; Xicoy, Blanca; García, Olga; Cabezón, Marta; Estrada, Natalia; Vélez, Patricia; Boque, Concepción; Sagüés, Miguel; Angona, Anna; Teruel-Montoya, Raúl; Ferrer-Marín, Francisca; Amat, Paula; Hernández-Boluda, Juan-Carlos; Ibarra, Mariana-M; Anguita, Eduardo; Cortés, Montserrat; Fernández-Ruiz, Andrés; Fontanals, Sandra; Zamora, Lurdes (MDPI, 2021-07)
    The most frequent BCR-ABL1-p210 transcripts in chronic myeloid leukemia (CML) are e14a2 and e13a2. Imatinib (IM) is the most common first-line tyrosine-kinase inhibitor (TKI) used to treat CML. Some studies suggest that ...
  • Integrating AIPSS-MF and molecular predictors: A comparative analysis of prognostic models for myelofibrosis 
    Mosquera-Orgueira, Adrián; Arellano-Rodrigo, Eduardo; Garrote, Marta; Martín, Iván; Pérez-Encinas, Manuel-Mateo; Gómez-Casares, María-Teresa; Hernández-Sánchez, Alberto; Ferrer-Marín, Francisca; Mora, Elvira; Vélez, Patricia; Ayala, Rosa; Angona, Anna; de-las-Heras, Natalia; Magro, Elena; Pérez-Míguez, Carlos; Crucitti, Davide; Mata-Vázquez, María-Isabel; Fox, María-Laura; González-de-Villambrosía, Sonia; Ramírez, María-José; García, Ana; García-Gutiérrez, Valentín; Cáceres, Amparo; Durán, María-Antonia; Senín, María-Alicia; Raya, José-María; González, José-A; Cuevas, Beatriz; Xicoy, Blanca; Nangalia, Jyoti; Hernández-Rivas, Jesús-María; Bellosillo, Beatriz; Álvarez-Larrán, Alberto; Hernández-Boluda, Juan-Carlos (John Wiley And Sons Inc, 2024)
    OBJECTIVE: To analyze the influence of the resting interval after removal of a double-balloon for cervical ripening and oxytocin administration on the time to onset of active labor in singleton pregnancies. METHODS: A ...
  • Machine Learning Improves Risk Stratification in Myelodysplastic Neoplasms: An Analysis of the Spanish Group of Myelodysplastic Syndromes 
    Mosquera-Orgueira, Adrián; Pérez-Encinas, Manuel-Mateo; Díaz-Varela, Nicolás-A; Mora, Elvira; Díaz-Beya, Marina; Montoro, María-Julia; Pomares, Helena; Ramos, Fernando; Tormo, Mar; Jerez-Cayuela, Andrés; Nomdedeu, Josep-F; de-Miguel-Sánchez, Carlos; Leonor, Arenillas; Carcel, Paula; Cedena, María-Teresa; Xicoy, Blanca; Rivero, Eugenia; del-Orbe-Barreto, Rafael-Andrés; Díez-Campelo, María; Benlloch, Luis-E; Crucitti, Davide; Valcárcel, David (WILEY, 2023-10)
    Myelodysplastic neoplasms (MDS) are a heterogeneous group of hematological stem cell disorders characterized by dysplasia, cytopenias, and increased risk of acute leukemia. As prognosis differs widely between patients, and ...
  • Machine Learning Improves Risk Stratification in Myelofibrosis: An Analysis of the Spanish Registry of Myelofibrosis 
    Mosquera-Orgueira, Adrián; Pérez-Encinas, Manuel-Mateo; Hernández-Sánchez, Alberto; González-Martínez, Teresa; Arellano-Rodrigo, Eduardo; Martínez-Elicegui, Javier; Villaverde-Ramiro, Ángela; Raya, José-María; Ayala, Rosa; Ferrer-Marín, Francisca; Fox, María-Laura; Vélez, Patricia; Mora, Elvira; Xicoy, Blanca; Mata-Vázquez, María-Isabel; García-Fortes, María; Angona, Anna; Cuevas, Beatriz; Senin, María-Alicia; Ramírez-Payer, Ángel; Ramírez, María-José; Pérez-López, Raúl; González-de-Villambrosía, Sonia; Martínez-Valverde, Clara; Gómez-Casares, María-Teresa; García-Hernández, Carmen; Gasior, Mercedes; Bellosillo, Beatriz; Steegman, Juan-Luis; Álvarez-Larrán, Alberto; Hernández-Rivas, Jesús-María; Hernández-Boluda, Juan-Carlos (WILEY, 2023-01)
    Myelofibrosis (MF) is a myeloproliferative neoplasm (MPN) with heterogeneous clinical course. Allogeneic hematopoietic cell transplantation remains the only curative therapy, but its morbidity and mortality require careful ...
  • One-year consolidation with Ponatinib 15 mg in chronic myeloid leukaemia on deep molecular response with Imatinib 
    Pérez-Lamas, Lucía; Manzanares, Mario; Hernández-Boluda, Juan-Carlos; Casado-Montero, Luis-Felipe; Gómez-Casares, María-Teresa; Ayala, Rosa; Xicoy, Blanca; Ferrer-Marín, Francisca; Orti, Guillermo; De-Paz-Arias, Raquel; Osorio-Prendes, Santiago; Pérez-López, Raúl; Mora, Elvira; Ruiz-Nuno, Concepción; Jiménez-Velasco, Antonio; Boque, Concepción; Sierra-Pacho, Magdalena; Martínez-López, Joaquín; Carreño-Tarragona, Gonzalo; Coiras, Mayte; García-Gutiérrez, Valentín (SPRINGERNATURE, 2026-01-20)
    Tyrosine kinase inhibitors (TKIs) discontinuation is the standard option for patients with chronic myeloid leukaemia (CML) in deep molecular response (MR) with imatinib. This study aimed to evaluate the efficacy and safety ...
  • Predicting Survival after Allogeneic Hematopoietic Cell Transplantation in Myelofibrosis: Performance of the Myelofibrosis Transplant Scoring System (MTSS) and Development of a New Prognostic Model 
    Hernández-Boluda, Juan-Carlos; Pereira, Arturo; Álvarez-Larrán, Alberto; Martín, Ana-África; Benzaquen, Ana; Aguirre, Lourdes; Mora, Elvira; González, Pedro; Mora, Jorge; Dorado, Nieves; Sampol, Antonia; García-Gutiérrez, Valentín; López-Godino, Oriana; Fox, María-Laura; Reguera, Juan-Luis; Pérez-Encinas, Manuel-Mateo; Pascual, María-Jesus; Xicoy, Blanca; Parody, Rocío; González-Pinedo, Leslie; Español, Ignacio; Avendano, Alejandro; Correa, Juan-Gonzalo; Vallejo, Carlos; Jurado, Manuel; García-Cadenas, Irene; Osorio, Santiago; Durán, María-Antonia; Sánchez-Guijo, Fermín; Cervantes, Francisco; Piñana, José-Luis (ELSEVIER SCIENCE INC, 2020-12)
    Accurate prognostic tools are crucial to assess the risk/benefit ratio of allogeneic hematopoietic cell transplantation (allo-HCT) in patients with myelofibrosis (MF). We aimed to evaluate the performance of the Myelofibrosis ...
  • Real world outcomes of momelotinib in myelofibrosis patients with anemia: results from the MOMGEMFIN study 
    Pérez-Lamas, Lucía; Segura-Díaz, Adrián; García-Delgado, Regina; Álvarez-Larran, Alberto; Senin, María-Alicia; Mora, Elvira; Fox, María-Laura; Pastor-Galan, Irene; Azaceta, Gemma; Garrido-Paniagua, Sara; Pérez-López, Raúl; Trejos-Carvajal, Diana-Margarita; Angona, Anna; Albo-López, Carmen; Lorente-Alegre, Pablo; Vara, Miriam; Vera-Goni, Juan-Antonio; De-Miguel-Llorente, Dunia; Fernández-Rodríguez, Ángeles; Marín-Sánchez, Alberto; Hernando-Megido, Adriana; Gómez-Casares, María-Teresa; Stuckey, Ruth; Carreno-Tarragona, Gonzalo; De-Las-Heras-Rodríguez, Natalia; Xicoy, Blanca; Pérez-Encinas, Manuel; Mata-Serna, Raquel; Núñez-Martín-Buitrago, Lucía; Ferrer-Marín, Francisca; Amer-Salas, Neus; Guillén-Rienda, Carolina; Velez, Patricia; Lamarca-Eraso, Laura; Martin, Sandra; Luts-Khoroz, Iryna; De-Cabo-López, Erik; Gil, Ángela; Martín-Consuegra-Ramos, Sofia; Marco-de-Lucas, Fernando; Otero-Martínez-Fornes, María-José; Martín-Mateos, María-Luisa; Arquero, Teresa; Cabezudo-Pérez, Elena; López-Gómez, Luis-Antonio; Martínez-Hellin, Ángela; Tejedor-Gutiérrez, Aurelia; Herrera-de-Pablo, Esther; Mata-Vázquez, María-Isabel; Castillo-Valero, Inmaculada; Fernández, María-José; Aguilar, Carlos; Santaliestra, Marta; García-Menchon, Antonio; Navas-Elorza, Begoña; Durán, María-Antonia; Pérez-Sala, María; Hernández-Santamaria, Teresa; Muñoz-Jarreno, María-Ángeles; Dávila-Valls, Julio; Torres-Jiménez, Williana; Gonzalvez-Fernández, Joan-Alfons; Torres-Mantilla, Hugo-Alexander; Cobo-Rodríguez, Teresa; Abuin-Blanco, Aitor; Pérez, Francisco; Osorio-Prendes, Santiago; Beneit-Villena, Paola; Peralta, Raisa; Herrera, Federico; Canamero-Giro, Eloi; Jiménez-Barcenas, Reyes; Gasior-Kabat, Mercedes; González-de-Villambrosia, Sonia; Tercero-Mora-Rodríguez, Mariana-Teresa; Menéndez-Cuevas, Marina; Cuevas-Ruiz, Beatriz; Fonseca-Santos, Marta; Garces-Piquer, Sonia; de-la-Puerta, Rosalía; Lorenzo-Vizcaya, Álvaro; Hernández-Boluda, Juan-Carlos; García-Gutiérrez, Valentín (SPRINGERNATURE, 2025-04-17)
  • Relevance of infections on the outcomes of patients with myelodysplastic syndromes, chronic myelomonocytic leukemia, and acute myeloid leukemia treated with hypomethylating agents: a cohort study from the GESMD 
    Vilorio-Marqués, Laura; Fernández, Christelle-Castanon; Mora, Elvira; Gutiérrez, Lorena; Rey-Bua, Beatriz; Jiménez-Lorenzo, María-José; Díaz-Beya, Marina; Vara-Pampliega, Miriam; Molero, Antonieta; Sánchez-García, Joaquín; Calabuig, Marisa; Cedena, María-Teresa; Chen-Liang, Tzu-Hua; Díaz-Santa, Johana-Alejandra; Padilla, Irene; Hernández, Francisca; Díez, Rosana; Asensi, Pedro; Xicoy, Blanca; Sanz, Guillermo; Valcárcel, David; Díez-Campelo, María; Bernal, Teresa (SAGE PUBLICATIONS LTD, 2022-09)
    BACKGROUND: The consequences of infectious toxicity of hypomethylating agents (HMAs) on overall survival (OS) of patients diagnosed with high-risk myeloid neoplasms have not been thoroughly investigated. OBJECTIVES: We ...
  • ROP-ET: a prospective phase III trial investigating the efficacy and safety of ropeginterferon alfa-2b in essential thrombocythemia patients with limited treatment options 
    Kiladjian, Jean-Jacques; Ferrer-Marín, Francisca; Al-Ali, Haifa-Kathrin; Álvarez-Larrán, Alberto; Beggiato, Eloise; Bieniaszewska, María; Breccia, Massimo; Buxhofer-Ausch, Veronika; Cerna, Olga; Crisan, Ana-Manuela; Danaila, Catalin-Doru; de-Stefano, Valerio; Doehner, Konstanze; Empson, Victoria; Gora-Tybor, Joanna; Griesshammer, Martín; Grosicki, Sebastián; Guglielmelli, Paola; García-Gutiérrez, Valentín; Heidel, Florian-H; Illes, Arpad; Tomuleasa, Ciprian; James, Chloe; Koschmieder, Steffen; Krauth, María-Theresa; Krejcy, Kurt; Lázaroiu, Mihaela-Cornelia; Mayer, Jiri; Nagy, Zsolt-Gyoergy; Nicolini, Franck-Emmanuel; Palandri, Francesca; Pappa, Vassiliki; Reiter, Andreas-Johannes; Sacha, Tomász; Schlager, Stefanie; Schmidt, Stefan; Terpos, Evangelos; Unger, Martín; Woelfler, Albert; Xicoy, Blanca; Klade, Christoph (Springer, 2024-07)
    Interferon-based therapies, such as ropeginterferon alfa-2b have emerged as promising disease-modifying agents for myeloproliferative neoplasms (MPNs), including essential thrombocythemia (ET). Current ET treatments aim ...
  • Safety and efficacy of asciminib treatment in chronic myeloid leukemia patients in real-life clinical practice 
    García-Gutiérrez, Valentín; Luna, Alejandro; Alonso-Domínguez, Juan-Manuel; Estrada, Natalia; Boque, Concepción; Xicoy, Blanca; Giraldo, Pilar; Angona, Anna; Álvarez-Larrán, Alberto; Sánchez-Guijo, Fermín; Ramírez, María-José; Mora, Elvira; Vélez, Patricia; Rosell, Ana; Colorado-Araujo, Mercedes; Cuevas, Beatriz; Sagüés, Miguel; Cortés, Montserrat; Pérez-Encinas, Manuel-Mateo; Casado-Montero, Luis-Felipe; Moreno-Vega, Melania; Serrano, Luis; Gómez, Valle; García-Hernández, Carmen; Lakhwani, Sunil; Paz-Coll, Antonio; de-Paz, Raquel; Suárez-Varela, Sara; Fernández-Ruiz, Andrés; Pérez-López, Raúl; Ortiz-Fernández, Almudena; Jiménez-Velasco, Antonio; Steegmann-Olmedillas, Juan-Luis; Hernández-Boluda, Juan-Carlos (Springer Nature, 2021)
  • Toxic iron species in lower-risk myelodysplastic syndrome patients: course of disease and effects on outcome 
    Hoeks, Marlijn; Bagguley, Tim; van-Marrewijk, Corine; Smith, Alex; Bowen, David; Culligan, Dominic; Kolade, Seye; Symeonidis, Argiris; Garelius, Hege; Spanoudakis, Michail; Langemeijer, Saskia; Roelofs, Rian; Wiegerinck, Erwin; Tatic, Aurelia; Killick, Sally; Panagiotidis, Panagiotis; Stanca, Oana; Hellström-Lindberg, Eva; Cermak, Jaroslav; van-der-Klauw, Melanie; Wouters, Hanneke; van-Kraaij, Marian; Blijlevens, Nicole; Swinkels, Dorine-W; de-Witte, Theo; Stauder, R; Walder, A; Pfeilstöcker, M; Schoenmetzler-Makrai, A; Burgstaller, S; Thaler, J; Mandac-Rogulj, I; Krejci, M; Voglova, J; Rohon, P; Jonasova, A; Mikulenkova, D; Hochova, I; Jensen, PD; Holm, MS; Kjeldsen, L; Dufva, IH; Vestergaard, H; Re, D; Slama, B; Fenaux, P; Choufi, B; Cheze, S; Klepping, D; Salles, B; de-Renzis, B; Willems, L; de-Prost, D; Gutnecht, J; Courby, S; Siguret, V; Tertian, G; Pascal, L; Chaury, M; Wattel, E; Guerci, A; Legros, L; Itzykson, R; Ades, L; Isnard, F; Sanhes, L; Benramdane, R; Stamatoullas, A; Amé, S; Beyne-Rauzy, O; Gyan, E; Platzbecker, U; Badrakan, C; Germing, U; Lübbert, M; Schlenk, R; Kotsianidis, I; Tsatalas, C; Pappa, V; Galánopoulos, A; Michali, E; Panagiotidis, P; Viniou, N; Katsigiannis, A; Roussou, P; Terpos, E; Kostourou, A; Kartasis, Z; Pouli, A; Palla, K; Briasoulis, V; Hatzimichael, E; Vassilopoulos, G; Kourakli, A; Zikos, P; Anagnostopoulos, A; Kotsopoulou, M; Megalakaki, K; Protopapa, M; Vlachaki, E; Konstantinidou, P; Stemer, G; Nemetz, A; Gotwin, U; Cohen, O; Koren, M; Levy, E; Greenbaum, U; Gino-Moor, S; Price, M; Ofran, Y; Winder, A; Goldshmidt, N; Elias, S; Sabag, R; Hellman, I; Ellis, M; Braester, A; Rosenbaum, H; Berdichevsky, S; Itzhaki, G; Wolaj, O; Yeganeh, S; Katz, O; Filanovsky, K; Dali, N; Mittelman, M; Malcovati, L; Fianchi, L; vd-Loosdrecht, A; Matthijssen, V; Herbers, A; Pruijt, H; Aboosy, N; de-Vries, F; Velders, G; Jacobs, E; MacKenzie, M; Lensen, C; Kuijper, P; Madry, K; Cámara, M; Almeida, A; Vulkan, G; Stanca-Ciocan, O; Savic, A; Pedro, C; Xicoy, Blanca; Leiva, P; Muñoz, J; Betes, V; Benavente, C; Lozano, M; Martínez, M; Iniesta, P; Bernal, T; Díez-Campelo, María; Tormo, D; Andreu-Lapiedra, R; Sanz, G; Hesse-Sundin, E; Karlsson, C; Antunovic, P; Jönsson, A; Brandefors, L; Nilsson, L; Kozlowski, P; Grövdal, M; Larsson, K; Wallvik, J; Lorenz, F; Ejerblad, E; Craddock, C; Cahalin, P; Ackroyd, S; Wong, C; Warren, A; Drummond, M; Hall, C; Rothwell, K; Green, S; Ali, S; Karakantza, M; Dennis, M; Jones, G; Parker, J; Bowen, A; Radia, R; Das-Gupta, E; Vyas, P; Nga, E; Creagh, D; Ashcroft, J; Mills, J; Bond, L (Springer Nature, 2021)
  • Toxicity of Asciminib in Real Clinical Practice: Analysis of Side Effects and Cross-Toxicity with Tyrosine Kinase Inhibitors 
    Pérez-Lamas, Lucía; Luna, Alejandro; Boque, Concepción; Xicoy, Blanca; Giraldo, Pilar; Pérez-López, Raúl; Ruiz-Nuno, Concepción; de-las-Heras, Natalia; Mora-Castera, Elvira; López-Marin, Javier; Segura-Díaz, Adrián; Gómez, Valle; Vélez-Tenza, Patricia; Sierra-Pacho, Magdalena; Vera-Goni, Juan-Antonio; Moreno-Vega, Melania; Álvarez-Larrán, Alberto; Cortés, Montse; Pérez-Encinas, Manuel-Mateo; Carrascosa-Mastell, Patricia; Angona, Anna; Rosell, Ana; Lakhwani, Sunil; Colorado, Mercedes; Ramila, Elena; Cervero, Carlos; Cuevas, Beatriz; Villalón-Blanco, Lucía; de-Paz, Raquel; Paz-Coll, Antonio; Fernández, María-José; Felipe-Casado, Luis; Alonso-Domínguez, Juan-Manuel; Anguita-Arance, María-Magdalena; Salamanca-Cuenca, Araceli; Jiménez-Velasco, Antonio; Osorio-Prendes, Santiago; Santaliestra, Marta; Lis-Chulvi, María-José; Hernández-Boluda, Juan-Carlos; García-Gutiérrez, Valentín (MDPI, 2023-02)
    (1) Background: Despite the prognostic improvements achieved with tyrosine kinase inhibitors (TKIs) in chronic myeloid leukemia (CML), a minority of patients still fail TKIs. The recent introduction of asciminib may be a ...